Florida Super Lawyers Profiles Construction Attorney Kim Ashby
June 26, 2017
Florida Super Lawyers
Partner Kim Ashby was recently profiled in a Florida Super Lawyers article titled, “If You Build It… Kim Ashby Just Might Be Your Attorney.” This feature story is in conjunction with Ashby’s recognition in the 2017 Florida Super Lawyers ranking.
The article covers Ashby’s work on behalf of the Grande Lakes Resort in the Orlando area, includes quotes from individuals who work closely with her, and highlights strong aspects of her personal and professional lives. Read the full article here.
Twenty six Foley attorneys accompany Ashby in being named to the 2017 Florida Super Lawyers ranking. Click here for more information.
The article covers Ashby’s work on behalf of the Grande Lakes Resort in the Orlando area, includes quotes from individuals who work closely with her, and highlights strong aspects of her personal and professional lives. Read the full article here.
Twenty six Foley attorneys accompany Ashby in being named to the 2017 Florida Super Lawyers ranking. Click here for more information.
Related News
September 18, 2026
In the News
Patrick Daugherty Authors Article on Navigating Proposed SEC Crypto Asset Regulations
Foley & Lardner LLP partner Patrick Daugherty authored the Columbia Law School’s Blue Sky Blog article, “How to Advise Token Developers in Light of Proposed SEC Regulation Crypto Assets.”
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.